Contraindicated (one)bortezomib will increase the amount or impact of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or average CYP2C19 inhibitors may boost mavacamten systemic exposure, leading to heart failure as a result of systolic dysfunction. @fabs Should you preferred this, perhaps would you prefer Open up new window https://emilianokewpg.blogdeazar.com/26887777/indicators-on-thalicarpine-you-should-know